| Drug repurposing from the perspective of pharmaceutical companies Y Cha, T Erez, IJ Reynolds, D Kumar, J Ross, G Koytiger, R Kusko, ... British journal of pharmacology 175 (2), 168-180, 2018 | 373 | 2018 |
| Leveraging an NQO1 bioactivatable drug for tumor-selective use of poly (ADP-ribose) polymerase inhibitors X Huang, EA Motea, ZR Moore, J Yao, Y Dong, G Chakrabarti, JA Kilgore, ... Cancer cell 30 (6), 940-952, 2016 | 113 | 2016 |
| Pridopidine activates neuroprotective pathways impaired in Huntington Disease M Geva, R Kusko, H Soares, KD Fowler, T Birnberg, S Barash, ... Human molecular genetics 25 (18), 3975-3987, 2016 | 105 | 2016 |
| Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19) J Kim, J Zhang, Y Cha, S Kolitz, J Funt, R Escalante Chong, S Barrett, ... Journal of translational medicine 18, 1-9, 2020 | 83 | 2020 |
| Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice M Garcia-Miralles, M Geva, JY Tan, NABM Yusof, Y Cha, R Kusko, LJ Tan, ... JCI insight 2 (23), 2017 | 44 | 2017 |
| Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse R Kusko, J Dreymann, J Ross, Y Cha, R Escalante-Chong, ... Molecular Neurodegeneration 13, 1-15, 2018 | 36 | 2018 |
| pS421 huntingtin modulates mitochondrial phenotypes and confers neuroprotection in an HD hiPSC model X Xu, B Ng, B Sim, CI Radulescu, NABM Yusof, WI Goh, S Lin, JSY Lim, ... Cell Death & Disease 11 (9), 809, 2020 | 11 | 2020 |
| Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice. JCI Insight. 2017; 2 (23): e95665 M Garcia-Miralles, M Geva, JY Tan, N Yusof, Y Cha, R Kusko PubMed: https://pubmed. ncbi. nlm. nih. gov/29212949, 2017 | 10 | 2017 |
| Integrity, standards, and QC-related issues with big data in pre-clinical drug discovery JF Brothers II, M Ung, R Escalante-Chong, J Ross, J Zhang, Y Cha, ... Biochemical Pharmacology 152, 84-93, 2018 | 5 | 2018 |
| Pharma perspective on drug repurposing Y Cha, T Erez, IJ Reynolds, D Kumar, J Ross, G Koytiger, R Kusko, ... British Journal of Pharmacology 175 (2), 168-180, 2017 | 4 | 2017 |
| 477 Deep learning to drive COVID-19 rapid drug repurposing S Kolitz, J Kim, J Zhang, Y Cha, S Battula, R Kusko J Immunother 8 (3), A1-A559, 2020 | 2 | 2020 |
| 664 Applying advanced data analysis to immunotherapy drug discovery for Uveal Melanoma S Kolitz, Y Cha, S Battula, R Kusko, B Zeskind, H Kaufman Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020 | 1 | 2020 |
| Loss of the Sigma-1 receptor disrupts pridopidine-induced gene expression (P4. 048) J Dreymann, M Geva, J Ross, Y Cha, R Kusko, R Escalante-Chong, ... Neurology 90 (15 Supplement), 2018 | 1 | 2018 |
| Navigating the Frontiers of Machine Learning in Neurodegenerative Disease Therapeutics Y Cha, MN Kagalwala, J Ross Pharmaceuticals 17 (2), 158, 2024 | | 2024 |
| Abstract B027: A meta-metastasis analysis identifies pan-cancer markers and therapeutic targets KD Fowler, JM Funt, S Kolitz, J Zhang, M Ung, R Escalante-Chong, ... Molecular Cancer Therapeutics 17 (1_Supplement), B027-B027, 2018 | | 2018 |
| Leveraging transcriptomic and genomic data to better select models for preclinical oncology therapeutic development to identify cell lines most similar to patient tumors Y Cha, A Labradorf, J Perez-Rogers, B Haas, A Lysaght, B Weiner, ... Cancer Research 76 (14_Supplement), 789-789, 2016 | | 2016 |
| Leveraging transcriptomic data to pinpoint mechanisms of gemcitabine resistance and potential combination therapies for pancreatic cancer. RL Kusko, Y Cha, J Perez-Rogers, N Caballero, G Koytiger, J Shankar, ... Journal of Clinical Oncology 34 (15_suppl), e15730-e15730, 2016 | | 2016 |
| Abstract A78: Leveraging genomics to optimize models for accelerated pancreatic cancer drug development Y Cha, A Lysaght, B Weiner, S Kolitz, F Towfic, K Fowler, B Vardarajan, ... Molecular Cancer Therapeutics 14 (12_Supplement_2), A78-A78, 2015 | | 2015 |
| Improving pancreatic cancer drug discovery by leveraging genomics to select better in vitro models Y Cha, J Perez-Rogers, A Lysaght, B Weiner, S Kolitz, F Towfic, J Funt, ... Cell 10, C3, 2015 | | 2015 |
| Improving pre-clinical screening of drug candidates for pancreatic cancer by applying a systems genomics approach to pinpoint ideal cell line models. B Zeskind, Y Cha, A Lysaght, R Cui, B Weiner, S Kolitz, F Towfic, J Funt, ... Journal of Clinical Oncology 33 (15_suppl), e15268-e15268, 2015 | | 2015 |
